Search | Clinical Trials Finder

Conditions: Aging, Alzheimer Disease, Healthy Aging, Cognitive Change
Interventions: Cardio-Dance Fitness, Strength, Flexibility & Balance; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 60 Years and older
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Acromegaly
Interventions: Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Alzheimer's Disease
Interventions: Bryostatin 1, Placebo; Drug · Other
Lead sponsor: Neurotrope Bioscience, Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 29
States / cities: Phoenix, Arizona • Costa Mesa, California • Los Alamitos, California + 26 more

Conditions: Asthma
Interventions: Heart rate variability biofeedback, Placebo; Behavioral
Lead sponsor: Fred Wamboldt, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 2
States / cities: Denver, Colorado • Piscataway, New Jersey

Conditions: Healthy
Interventions: PF-07328948, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: COVID-19
Interventions: Resveratrol, Vitamin D3; Drug · Dietary Supplement
Lead sponsor: Marvin McCreary, MD; Other
Eligibility: 45 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Mediastinal or Intra-abdominal Lymphadenopathy,, Pancreatic Masses,, Left Adrenal Masses,, Gastrointestinal Submucosal Lesions, and, Liver Masses
Interventions: EUS - FNA with stylet, Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA); Device
Lead sponsor: American Society for Gastrointestinal Endoscopy; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Anemia, Sickle Cell
Interventions: Glutamine, Placebo; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Depression
Interventions: PEER Interactive Report; Device
Lead sponsor: MYnd Analytics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Insomnia Chronic
Interventions: CBT-I, MAP-I; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 45 Years to 95 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Loudness Hyperacusis, Autism Spectrum Disorder (ASD), Hyperacusis
Interventions: Transitional Intervention for Hyperacusis in Autism; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 39 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Orlando, Florida • Dallas, Texas

Conditions: POTS, POTS - Postural Orthostatic Tachycardia Syndrome, Dysautonomia, Autonomic Dysfunction
Interventions: Blood Sample Collection; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease
Interventions: ECHS AD Device; Device
Lead sponsor: Herrick Medical LLC; Industry
Eligibility: 50 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Child Behavior Disorders
Interventions: VillageWhere App, Attention-Control Placebo App; Device
Lead sponsor: Evidence-Based Practice Institute, Seattle, WA; Industry
Eligibility: 13 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Coping
Interventions: Formal Mindful Self-Compassion (MSC-F), Informal Mindful Self-Compassion (MSC-I); Behavioral
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 14 Years to 19 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Malden, Massachusetts

Conditions: Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cavity Cancer
Interventions: metformin hydrochloride, placebo, Chemotherapy; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more

Conditions: Eosinophilic Esophagitis
Interventions: APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy; Drug · Procedure
Lead sponsor: Ellodi Pharmaceuticals, LP; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 48
States / cities: Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more

Conditions: Chronic Gastrointestinal Graft vs Host Disease
Interventions: orBec, Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Hackensack, New Jersey • Buffalo, New York • Nashville, Tennessee

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo-matching dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 2,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 164
States / cities: Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more

Conditions: Atrial Fibrillation
Interventions: Alert for Atrial Fibrillation Program, Healthy Sleep; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Kidney Disease
Interventions: MEDI3506, Placebo, Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 42 more

Conditions: Pregnancy, Unplanned, Sexually Transmitted Diseases
Interventions: About Us; Behavioral
Lead sponsor: ETR Associates; Other
Eligibility: 14 Years to 18 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Oakland, California • San Diego, California • Scotts Valley, California

Conditions: 65 Years Older, Requires IADL Support, Past Year History of Falls and/or Hospitalization
Interventions: Elder Tree website; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 65 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Telemedicine, Counseling
Interventions: Preoperative counseling, Asynchronous telemedicine; Behavioral
Lead sponsor: Carilion Clinic; Other
Eligibility: Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Search by objective public record fields.

Exercise to Improve Brain Health in Older African Americans

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

A Randomized Controlled Trial Of Endoscopic Ultrasound-Guided Fine-Needle Aspiration With And Without A Stylet

Trial of Oral Glutamine in Patients With Sickle Cell Anemia

Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression

Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers

Transitional Intervention for Hyperacusis in Autism

Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19

Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease

VillageWhere: Innovative Mobile Technology for Youth With Conduct Disorder and Their Parents

The Effectiveness and Acceptability of Formal Versus Informal Mindful Self-Compassion for Adolescents

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

Feasibility Testing of the Alert for Atrial Fibrillation Program

A Phase 2b Diabetic Kidney Disease Study

A Healthy Relationships Program for Vulnerable Youth

Bring Communities and Technology Together for Healthy Aging

Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors